Thomas J. Herzfeld Advisors, Inc. Bei Gene, Ltd. Transaction History

Thomas J. Herzfeld Advisors, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$179.87 - $225.13 $3,957 - $4,952	22 New	22 $3.96 Million
Q1 2023 May 16, 2023	BUY	$215.53 - $274.5 $1,508 - $1,921	7 Added 46.67%	22 $4,000
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $878 - $1,101	3 Added 25.0%	15 $5,000
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $260 - $382	1 Added 9.09%	12 $4,000
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $663 - $949	-3 Reduced 21.43%	11 $3,000
Q2 2020 Aug 12, 2020	BUY	$123.9 - $195.41 $1,734 - $2,735	14 New	14 $3,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Thomas J. Herzfeld Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Thomas J. Herzfeld Advisors, Inc. with notifications on news.